Vizsgálati helyszín
Jagiellonskie Centrum Innowacji Sp. z o.o.
Cracow, 30-348, LengyelországEU-13 felzárkózó országMég nincs intézményhez kötve
- 17futó vizsgálat
- 9lezárt vizsgálat
Az itteni vizsgálatok
Miről szól a helyszín 26 vizsgálata, a regiszteri adatlapjaik szerint.
- Fázis
- 3. fázis16 vizsgálat
- 2. fázis6 vizsgálat
- 1. fázis1 vizsgálat
- 1/2. fázis1 vizsgálat
- 2/3. fázis1 vizsgálat
- 4. fázis1 vizsgálat
- Állapot
- Lezárult9 vizsgálat
- Toboroz9 vizsgálat
- Fut, nem toboroz7 vizsgálat
- Még nem toboroz1 vizsgálat
- Fő szponzor
- Pfizer10 vizsgálat
- EMD Serono Research & Development Institute, Inc.3 vizsgálat
- AstraZeneca2 vizsgálat
- Bluefin Biomedicine Inc.1 vizsgálat
- Evommune Inc.1 vizsgálat
- és még 9
Futó vizsgálatok
Toboroz
Phase 3 Study of Azenosertib Versus Chemotherapy in Platinum-Resistant Ovarian Cancers Positive for Cyclin E1 Protein Expression
2025-524641-27-00· 3. fázis· K-Group Beta Inc.· Forrás
Toboroz
A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03)
NCT07549412· 3. fázis· EMD Serono Research & Development Institute, Inc.· Forrás
Toboroz
A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease
NCT07332481· 3. fázis· EMD Serono Research & Development Institute, Inc.· Forrás
Toboroz
A Study to Learn About Study Medicine Called PF-08049820 in People With Eczema
NCT07216027· 2. fázis· Pfizer· Forrás
Toboroz
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
NCT07144280· 3. fázis· Pfizer· Forrás
Toboroz
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
NCT07062965· 3. fázis· Pfizer· Forrás
Toboroz
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib
NCT06855498· 3. fázis· Incyte Corporation· Forrás
Fut, nem toboroz
Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer
NCT06619236· 3. fázis· Genmab· Forrás
Fut, nem toboroz
Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease
NCT06760637· 3. fázis· Pfizer· Forrás
Fut, nem toboroz
A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.
NCT06629779· 3. fázis· Pfizer· Forrás
Fut, nem toboroz
A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1).
NCT06551324· 3. fázis· Pfizer· Forrás
Fut, nem toboroz
A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis (ICONIC-ADVANCE 2)
NCT06220604· 3. fázis· Janssen Research & Development, LLC· Forrás
Toboroz
Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical)
NCT06079671· 3. fázis· AstraZeneca· Forrás
Fut, nem toboroz
A Study to Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People Who Have Advanced Metastatic Breast Cancer
NCT05654623· 3. fázis· Pfizer· Forrás
Toboroz
A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer
NCT05128825· 2. fázis· K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc· Forrás
Fut, nem toboroz
Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCC
NCT05043090· 3. fázis· AstraZeneca· Forrás
Toboroz
A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
NCT03460977· 1. fázis· Pfizer· Forrás
Egyszerre toboroz
Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.
Lezárt vizsgálatok
Lezárult
A Study Evaluating BFB759 in Atopic Dermatitis
2025-521624-30-00· 2. fázis· Bluefin Biomedicine Inc.· Forrás
Lezárult
The effects of 2-week long treatment with naproxen sodium (Nalgesin® Forte) on synovial fluid cytokine and naproxen concentration and clinical outcomes in patients with knee osteoarthritis – ZOOM-IN: A randomized, double-blind, placebo-controlled, parallel, multicentre clinical trial
2023-505875-56-00· 4. fázis· KRKA tovarna zdravil d.d. Novo mesto· Forrás
Lezárult
Dose-ranging study evaluating the efficacy and safety of EVO756 in adults with Chronic Spontaneous Urticaria.
2024-518786-10-01· 2. fázis· Evommune Inc.· Forrás
Lezárult
Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302)
NCT06433219· 2. fázis· EMD Serono Research & Development Institute, Inc.· Forrás
Lezárult
Study of IMG-007 in Participants with Moderate to Severe Atopic Dermatitis
NCT05984784· 1/2. fázis· Inmagene LLC· Forrás
Fut, nem toboroz
A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment
NCT06105632· 2. fázis· Pfizer· Forrás
Lezárult
Phase 2/3 Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer
2022-502196-31-00· 2/3. fázis· Kartos Therapeutics Inc.· Forrás
Lezárult
A Study of Olezarsen (ISIS 678354) in Participants With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease, or With Severe Hypertriglyceridemia
NCT05610280· 3. fázis· Ionis Pharmaceuticals, Inc.· Forrás
Lezárult
An Efficacy, Safety, Tolerability, Immunogenicity, and Lot-Consistency Clinical Trial of a 6-Valent OspA-Based Lyme Disease Vaccine (VLA15)
NCT05477524· 3. fázis· Pfizer· Forrás
Hibát jelzek